ALGORAE PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 AUD | 0.00% |
|
-9.09% | 0.00% |
| Mar. 08 | Algorae Pharmaceuticals Nears Launch of Drug Discovery Platform | MT |
| Feb. 28 | Algorae Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Sales 2022 | 3.4K 2.22K | Sales 2023 | 42.02K 27.44K | Capitalization | 23.4M 15.29M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -653K | Net income 2023 | -2M -1.31M | EV / Sales 2022 | 1,775 x |
| Net cash position 2022 | 4.24M 2.77M | Net cash position 2023 | 4.11M 2.69M | EV / Sales 2023 | 459 x |
| P/E ratio 2022 |
-3.58
x | P/E ratio 2023 |
-9.38
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.39% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -9.09% | ||
| 1 month | +11.11% | ||
| 3 months | +11.11% | ||
| 6 months | -9.09% |
1 week
0.01
0.01
1 month
0.010.01
Current year
0.010.01
1 year
0.010.02
3 years
0.000.02
5 years
0.000.06
10 years
0.000.28
| Managers | Title | Age | Since |
|---|---|---|---|
Daya Uka
DFI | Director of Finance/CFO | - | 15-12-31 |
James Mckenna
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-18 |
| Chief Operating Officer | - | 21-12-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Hainsworth
CHM | Chairman | 50 | 22-10-30 |
Bradley Dilkes
BRD | Director/Board Member | 39 | 22-10-30 |
Bradley Latham
BRD | Director/Board Member | 62 | 23-07-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.01 | 0.00% | 1,835,709 |
| 24-04-24 | 0.01 | 0.00% | 1,581,361 |
| 24-04-23 | 0.01 | 0.00% | 1,294,618 |
| 24-04-22 | 0.01 | -9.09% | 2,268,829 |
| 24-04-19 | 0.011 | 0.00% | 4,427,760 |
Delayed Quote Australian S.E., April 26, 2024 at 02:10 am EDT
More quotes
Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an Australia-based pharmaceutical development company. The Company is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinsonâs. Its drug candidates include NTCELL for Parkinsonâs disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinsonâs disease.
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 11M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 1AI Stock
